Table 1.
Study Cohort and Participant Characteristics by Vaccination Group
| Vaccinated Then Infected | Infected Then Vaccinated | Never Vaccinated | P Value | |
|---|---|---|---|---|
| n = 28 | n = 101 | n = 53 | n = 182 | |
| Age at time of consent, mean (SD), y | 52.0 (15.5) | 50.4 (14.5) | 49.4 (14.2) | .744 |
| Sex assigned at birth, No. (%) | .453 | |||
| Male | 10 (35.7) | 38 (37.6) | 25 (47.2) | |
| Female | 18 (64.3) | 63 (62.4) | 28 (52.8) | |
| BMI, mean (SD), kg/m2 | 28.0 (8.09) | 30.3 (7.2) | 30.5 (7.6) | .351 |
| Cancer, No. (%) | .017 | |||
| Blood-type cancers | 4 (15.38) | 9 (9.57) | 4 (8.16) | |
| Other cancers | 0 (0) | 0 (0) | 5 (10.2) | |
| Autoimmune disease, No. (%) | 6 (26.09) | 7 (7.45) | 4 (8.0) | .057 |
| Hypertension, No. (%) | 9 (36.0) | 40 (42.55) | 18 (36.0) | .675 |
| Race/ethnicity, No. (%) | .107 | |||
| Non-Hispanic White | 19 (67.9) | 46 (45.5) | 18 (34.0) | |
| African American | 7 (25.0) | 32 (31.7) | 25 (47.2) | |
| Non-Hispanic other | 0 (0.00) | 7 (6.9) | 3 (5.7) | |
| Hispanic | 2 (7.1) | 16 (15.8) | 7 (13.2) | |
| Type of 1st dose vaccine, No. (%) | .155 | |||
| Pfizer-BioNTech | 19 (67.9) | 73 (72.3) | 0 (0.0) | |
| Moderna-NIAID | 6 (21.4) | 26 (25.7) | 0 (0.0) | |
| Johnson & Johnson-Janssen | 3 (10.7) | 2 (2.0) | 0 (0.0) | |
| Type of 2nd dose vaccine, No. (%) | 1.00 | |||
| Pfizer-BioNTech | 20 (74.1) | 71 (72.5) | 0 (0.0) | |
| Moderna-NIAID | 7 (25.9) | 27 (27.5) | 0 (0.0) | |
| Type of 3rd dose vaccine, No. (%) | .495 | |||
| Pfizer-BioNTech | 16 (69.6) | 40 (80.0) | 0 (0.0) | |
| Moderna-NIAID | 7 (30.4) | 10 (20.0) | 0 (0.0) | |
| Days from infection to 1st dose vaccine, mean (SD) | −135.0 (100.4) | 226.1 (120.4) | <.001 | |
| Days from infection to 2nd dose vaccine, mean (SD) | −97.5 (124) | 245 (113.8) | <.001 |
Abbreviations: BMI, body mass index; NIAID, National Institute of Allergy and Infectious Diseases.